ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last2,401 to 2,420 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Basic Implementation Approach vs Enhanced Implementation Approach: Presence of an Order for Benzodiazepine Medication1,025 of 1,519

1,117 of 1,687

1.3 points

-2.0 to 4.5

3,206NCT02383173

Evaluation of Methods for Implementation of a Comfort Care Order Set

Basic Implementation Approach vs Enhanced Implementation Approach: Presence of Restraints86 of 1,519

73 of 1,687

1.3 points

-0.2 to 2.9

3,206NCT02383173

Evaluation of Methods for Implementation of a Comfort Care Order Set

Basic Implementation Approach vs Enhanced Implementation Approach: Presence of an Active Opioid Order at Time of Death1,330 of 1,519

1,543 of 1,687

-3.9 points

-6.1 to -1.8

3,206NCT02383173

Evaluation of Methods for Implementation of a Comfort Care Order Set

Fasiglifam 50 mg vs Placebo: serious adverse events201 of 1,601

197 of 1,603

0.3 points

-2.0 to 2.6

3,204NCT01609582

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

CYD Dengue Vaccine Group vs Control Group: deaths from any cause3 of 2,131

2 of 1,072

-0.0 points

-0.5 to 0.3

3,203NCT01983553

Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study

CYD Dengue Vaccine Group vs Control Group: serious adverse events3 of 2,131

2 of 1,072

-0.0 points

-0.5 to 0.3

3,203NCT01983553

Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study

R10933 + R10987 vs Placebo: Immunogenicity as Measured by Anti-drug Antibodies (ADAs) to REGN109331,319 of 1,595

1,544 of 1,606

-13.4 points

-15.6 to -11.4

3,201NCT04452318

COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay

R10987 + R10987 vs Placebo: Immunogenicity as Measured by Neutralizing Anti-drug Antibody (NAb) to REGN10987160 of 1,595

27 of 1,606

8.4 points

6.8 to 10.0

3,201NCT04452318

COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay

R10987 +R10933 vs Placebo: Immunogenicity as Measured by Anti-drug Antibodies (ADAs) to REGN109871,251 of 1,595

1,500 of 1,606

-15.0 points

-17.3 to -12.6

3,201NCT04452318

COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay

R10933 + R10987 vs Placebo: Immunogenicity as Measured by Neutralizing Anti-drug Antibody (NAb) to REGN1093333 of 1,595

4 of 1,606

1.8 points

1.1 to 2.7

3,201NCT04452318

COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay

Conventional Dispatcher CPR vs NAD-CPR: Number of Participants With Pre-Hospital Return of Spontaneous Circulation (ROSC)107 of 1,498

223 of 1,696

-6.0 points

-8.1 to -3.9

3,194NCT02010151

Dispatcher-Activated Neighborhood Access Defibrillation and Cardiopulmonary Resuscitation

Conventional Dispatcher CPR vs NAD-CPR: deaths from any cause1,363 of 1,498

1,480 of 1,696

3.7 points

1.6 to 5.9

3,194NCT02010151

Dispatcher-Activated Neighborhood Access Defibrillation and Cardiopulmonary Resuscitation

Conventional Dispatcher CPR vs NAD-CPR: Number of Participants With Good Neurological Recovery68 of 1,498

140 of 1,696

-3.7 points

-5.4 to -2.0

3,194NCT02010151

Dispatcher-Activated Neighborhood Access Defibrillation and Cardiopulmonary Resuscitation

Conventional Dispatcher CPR vs NAD-CPR: Number of Participants Surviving at Hospital Discharge135 of 1,498

216 of 1,696

-3.7 points

-5.9 to -1.6

3,194NCT02010151

Dispatcher-Activated Neighborhood Access Defibrillation and Cardiopulmonary Resuscitation

Conventional Dispatcher CPR vs NAD-CPR: serious adverse events1,363 of 1,498

1,480 of 1,696

3.7 points

1.6 to 5.9

3,194NCT02010151

Dispatcher-Activated Neighborhood Access Defibrillation and Cardiopulmonary Resuscitation

aH5N1c vs Placebo: deaths from any cause11 of 2,395

1 of 796

0.3 points

-0.3 to 0.7

3,191NCT02839330

A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age

aH5N1c vs Placebo: serious adverse events161 of 2,395

74 of 796

-2.6 points

-5.0 to -0.5

3,191NCT02839330

A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age

Intervention vs Control: Severe Maternal Outcome25 of 1,552

25 of 1,639

0.1 points

-0.8 to 1.0

3,191NCT04060667

Wireless Physiologic Monitoring in Postpartum Women

Part 1A: mRNA-1273 100 μg vs Part 1A: Placebo: Part 1A Number of Participants With a First Occurrence of Symptomatic COVID-190 of 2,142

6 of 1,044

-0.6 points

-1.2 to -0.2

3,186NCT04649151

A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19

Part 1A: mRNA-1273 100 μg vs Part 1A: Placebo: Part 1A Number of Participants With Asymptomatic SARS-CoV-2 Infection20 of 2,142

16 of 1,044

-0.6 points

-1.6 to 0.2

3,186NCT04649151

A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=121"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=121

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT02383173-3ad863be",
        "title": "Basic Implementation Approach vs Enhanced Implementation Approach: Presence of an Order for Benzodiazepine Medication",
        "summary": "1025 of 1519 against 1117 of 1687; risk difference 1.3 points, 95% interval -2.0 to 4.5; NCT02383173, Evaluation of Methods for Implementation of a Comfort Care Order Set",
        "record": "/library/comparisons/NCT02383173-3ad863be",
        "nct_id": "NCT02383173",
        "kind": "outcome",
        "participants": 3206,
        "risk_difference": {
          "value": 0.012663933194747568,
          "lower": -0.019995564954954782,
          "upper": 0.04519638484719493
        },
        "group_1": "1,025 of 1,519",
        "group_2": "1,117 of 1,687",
        "difference": "1.3 points",
        "interval": "-2.0 to 4.5",
        "trial_title": "Evaluation of Methods for Implementation of a Comfort Care Order Set"
      },
      {
        "id": "NCT02383173-67460b5e",
        "title": "Basic Implementation Approach vs Enhanced Implementation Approach: Presence of Restraints",
        "summary": "86 of 1519 against 73 of 1687; risk difference 1.3 points, 95% interval -0.2 to 2.9; NCT02383173, Evaluation of Methods for Implementation of a Comfort Care Order Set",
        "record": "/library/comparisons/NCT02383173-67460b5e",
        "nct_id": "NCT02383173",
        "kind": "outcome",
        "participants": 3206,
        "risk_difference": {
          "value": 0.013344114248563833,
          "lower": -0.001742320251744367,
          "upper": 0.028813031239893386
        },
        "group_1": "86 of 1,519",
        "group_2": "73 of 1,687",
        "difference": "1.3 points",
        "interval": "-0.2 to 2.9",
        "trial_title": "Evaluation of Methods for Implementation of a Comfort Care Order Set"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=122",
  "request_id": "1Dgd0o7oNY5QgGsb"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?